[HTML][HTML] Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
I Velikyan, O Eriksson - Theranostics, 2020 - ncbi.nlm.nih.gov
I Velikyan, O Eriksson
Theranostics, 2020•ncbi.nlm.nih.govIn the light of theranostics/radiotheranostics and prospective of personalized medicine in
diabetes and oncology, this review presents prior and current advances in the development
of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like
peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such
critical aspects as structure-activity-relationship, stability, physiological potency, kidney
uptake, and dosimetry are discussed.
diabetes and oncology, this review presents prior and current advances in the development
of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like
peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such
critical aspects as structure-activity-relationship, stability, physiological potency, kidney
uptake, and dosimetry are discussed.
Abstract
In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
ncbi.nlm.nih.gov